Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.
We recently compiled a list of the 10 Best Cancer Stocks To Buy Now. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against the other cancer stocks. Global Oncology Market Overview and Drug Shortages In 2022, the global oncology market was valued at approximately $203.42 billion and is […]
HTHIY vs. DHR: Which Stock Is the Better Value Option?